PIK3CA and colorectal cancer: This could be due to the absence of PIK3CA mutation in half of colorectal cancer patients, and the frequent co-occurrence of KRAS pathogenic variants with PIK3CA mutations, leading to a shorter reported PFS and potentially reduced activity against PIK3CA inhibitors.